GlassScriptPhysician profile
Arezoo Ghaneie
NPI 1790853497
$16,092.10
in general payments reported to CMS, 2019-2025
72 companies · $6,475 in 2025
The $6,475 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $342 · 2021: $656 · 2022: $1,823 · 2023: $3,121 · 2024: $3,114 · 2025: $6,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,672 · Consulting Fee: $3,745 · Education: $253 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,672.45 |
| Consulting Fee | $3,745.00 |
| Education | $252.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,708.70 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Galvanize Therapeutics, INC | $1,533.83 | 2025 | Aliya System |
| Novartis Pharmaceuticals Corporation | $1,081.97 | 2019-2025 | Kisqali |
| Lilly USA, LLC | $702.10 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $648.83 | 2022-2025 | Padcev, Xtandi, Xospata |
| Pfizer INC. | $613.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $527.01 | 2019-2024 | Opdivo, Opdualag |
| Genzyme Corporation | $512.51 | 2019-2025 | |
| Eisai INC. | $459.37 | 2022-2025 | |
| Celgene Corporation | $448.46 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $384.07 | 2020-2023 | Tukysa, Adcetris, Padcev |
| Genentech USA, INC. | $382.00 | 2019-2025 | Venclexta, Tecentriq, Alecensa |
| Merck Sharp & Dohme LLC | $348.43 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $346.38 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Janssen Biotech, INC. | $340.32 | 2019-2025 | Tecvayli, Carvykti, Talvey |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arezoo Ghaneie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.